Do analysts rate ALEC or EXOZ?

Alector presently has a consensus price target of $3.63, indicating a potential upside of 59.27%. Given Alector's stronger consensus rating and higher probable upside, analysts plainly believe Alector is more favorable than eXoZymes. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alector 2 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.13 eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, ALEC or EXOZ?

eXoZymes has lower revenue, but higher earnings than Alector. eXoZymes is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alector $21.05M 12.07 -$142.93M -$1.10 N/A eXoZymes $70K 949.21 -$9.16M -$1.19 N/A

Is ALEC or EXOZ more profitable?

eXoZymes has a net margin of 0.00% compared to Alector's net margin of -850.13%. eXoZymes' return on equity of -292.15% beat Alector's return on equity. Company Net Margins Return on Equity Return on Assets Alector -850.13% -531.03% -44.00% eXoZymes N/A -292.15% -158.66%

Does the media prefer ALEC or EXOZ?

In the previous week, Alector had 5 more articles in the media than eXoZymes. MarketBeat recorded 7 mentions for Alector and 2 mentions for eXoZymes. Alector's average media sentiment score of 1.47 beat eXoZymes' score of 0.93 indicating that Alector is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alector 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive eXoZymes 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate MGNX or EXOZ?

MacroGenics presently has a consensus price target of $6.33, suggesting a potential upside of 57.19%. Given MacroGenics' stronger consensus rating and higher probable upside, equities analysts plainly believe MacroGenics is more favorable than eXoZymes. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MacroGenics 1 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17 eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is MGNX or EXOZ more profitable?

eXoZymes has a net margin of 0.00% compared to MacroGenics' net margin of -8.70%. MacroGenics' return on equity of -109.26% beat eXoZymes' return on equity. Company Net Margins Return on Equity Return on Assets MacroGenics -8.70% -109.26% -18.70% eXoZymes N/A -292.15% -158.66%

Does the media prefer MGNX or EXOZ?

In the previous week, MacroGenics had 2 more articles in the media than eXoZymes. MarketBeat recorded 4 mentions for MacroGenics and 2 mentions for eXoZymes. MacroGenics' average media sentiment score of 1.66 beat eXoZymes' score of 0.93 indicating that MacroGenics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MacroGenics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive eXoZymes 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend EXOZ or EBS?

Emergent Biosolutions has a consensus price target of $10.00, suggesting a potential upside of 67.31%. Given Emergent Biosolutions' stronger consensus rating and higher possible upside, analysts clearly believe Emergent Biosolutions is more favorable than eXoZymes. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Emergent Biosolutions 2 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.17

Does the media refer more to EXOZ or EBS?

In the previous week, Emergent Biosolutions had 7 more articles in the media than eXoZymes. MarketBeat recorded 9 mentions for Emergent Biosolutions and 2 mentions for eXoZymes. eXoZymes' average media sentiment score of 0.93 beat Emergent Biosolutions' score of 0.92 indicating that eXoZymes is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment eXoZymes 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Emergent Biosolutions 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer EXOZ or PYXS?

Pyxis Oncology has a consensus target price of $7.50, indicating a potential upside of 139.92%. Given Pyxis Oncology's stronger consensus rating and higher possible upside, analysts clearly believe Pyxis Oncology is more favorable than eXoZymes. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Pyxis Oncology 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70

Is EXOZ or PYXS more profitable?

Pyxis Oncology's return on equity of -215.23% beat eXoZymes' return on equity. Company Net Margins Return on Equity Return on Assets eXoZymes N/A -292.15% -158.66% Pyxis Oncology N/A -215.23% -112.19%

Do analysts rate EXOZ or AKBA?

Akebia Therapeutics has a consensus price target of $3.75, suggesting a potential upside of 332.03%. Given Akebia Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Akebia Therapeutics is more favorable than eXoZymes. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Akebia Therapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33

Does the media refer more to EXOZ or AKBA?

In the previous week, Akebia Therapeutics had 2 more articles in the media than eXoZymes. MarketBeat recorded 4 mentions for Akebia Therapeutics and 2 mentions for eXoZymes. eXoZymes' average media sentiment score of 0.93 beat Akebia Therapeutics' score of 0.71 indicating that eXoZymes is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment eXoZymes 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Akebia Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

eXoZymes (EXOZ) Competitors

$7.16 -0.01 (-0.14%)

As of 10:35 AM Eastern

Compare

EXOZ vs. ALEC, MGNX, EBS, PYXS, and AKBA

Should you buy eXoZymes stock or one of its competitors? eXoZymes's main competitors and comparable companies include Alector (ALEC), MacroGenics (MGNX), Emergent Biosolutions (EBS), Pyxis Oncology (PYXS), and Akebia Therapeutics (AKBA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does eXoZymes compare to Alector?

Alector (NASDAQ:ALEC) and eXoZymes (NASDAQ:EXOZ) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, valuation, risk and analyst recommendations.

85.8% of Alector shares are held by institutional investors. 8.3% of Alector shares are held by insiders. Comparatively, 72.4% of eXoZymes shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Alector presently has a consensus price target of $3.63, indicating a potential upside of 59.27%. Given Alector's stronger consensus rating and higher probable upside, analysts plainly believe Alector is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Alector has a beta of 0.6, suggesting that its stock price is 40% less volatile than the broader market. Comparatively, eXoZymes has a beta of 2.93, suggesting that its stock price is 193% more volatile than the broader market.

eXoZymes has lower revenue, but higher earnings than Alector. eXoZymes is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alector	$21.05M	12.07	-$142.93M	-$1.10	N/A
eXoZymes	$70K	949.21	-$9.16M	-$1.19	N/A

In the previous week, Alector had 5 more articles in the media than eXoZymes. MarketBeat recorded 7 mentions for Alector and 2 mentions for eXoZymes. Alector's average media sentiment score of 1.47 beat eXoZymes' score of 0.93 indicating that Alector is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alector	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
eXoZymes	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

eXoZymes has a net margin of 0.00% compared to Alector's net margin of -850.13%. eXoZymes' return on equity of -292.15% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alector	-850.13%	-531.03%	-44.00%
eXoZymes	N/A	-292.15%	-158.66%

Summary

Alector beats eXoZymes on 10 of the 16 factors compared between the two stocks.

How does eXoZymes compare to MacroGenics?

MacroGenics (NASDAQ:MGNX) and eXoZymes (NASDAQ:EXOZ) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation.

eXoZymes has lower revenue, but higher earnings than MacroGenics. MacroGenics is trading at a lower price-to-earnings ratio than eXoZymes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MacroGenics	$175.14M	1.47	-$74.62M	-$0.22	N/A
eXoZymes	$70K	949.21	-$9.16M	-$1.19	N/A

In the previous week, MacroGenics had 2 more articles in the media than eXoZymes. MarketBeat recorded 4 mentions for MacroGenics and 2 mentions for eXoZymes. MacroGenics' average media sentiment score of 1.66 beat eXoZymes' score of 0.93 indicating that MacroGenics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MacroGenics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
eXoZymes	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

eXoZymes has a net margin of 0.00% compared to MacroGenics' net margin of -8.70%. MacroGenics' return on equity of -109.26% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MacroGenics	-8.70%	-109.26%	-18.70%
eXoZymes	N/A	-292.15%	-158.66%

MacroGenics presently has a consensus price target of $6.33, suggesting a potential upside of 57.19%. Given MacroGenics' stronger consensus rating and higher probable upside, equities analysts plainly believe MacroGenics is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

96.9% of MacroGenics shares are owned by institutional investors. 13.6% of MacroGenics shares are owned by insiders. Comparatively, 72.4% of eXoZymes shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

MacroGenics has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market. Comparatively, eXoZymes has a beta of 2.93, suggesting that its share price is 193% more volatile than the broader market.

Summary

MacroGenics beats eXoZymes on 10 of the 16 factors compared between the two stocks.

How does eXoZymes compare to Emergent Biosolutions?

eXoZymes (NASDAQ:EXOZ) and Emergent Biosolutions (NYSE:EBS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation.

In the previous week, Emergent Biosolutions had 7 more articles in the media than eXoZymes. MarketBeat recorded 9 mentions for Emergent Biosolutions and 2 mentions for eXoZymes. eXoZymes' average media sentiment score of 0.93 beat Emergent Biosolutions' score of 0.92 indicating that eXoZymes is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
eXoZymes	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Emergent Biosolutions	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

eXoZymes has a net margin of 0.00% compared to Emergent Biosolutions' net margin of -22.95%. Emergent Biosolutions' return on equity of 16.35% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
eXoZymes	N/A	-292.15%	-158.66%
Emergent Biosolutions	-22.95%	16.35%	6.17%

78.4% of Emergent Biosolutions shares are held by institutional investors. 72.4% of eXoZymes shares are held by insiders. Comparatively, 6.0% of Emergent Biosolutions shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Emergent Biosolutions has higher revenue and earnings than eXoZymes. eXoZymes is trading at a lower price-to-earnings ratio than Emergent Biosolutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
eXoZymes	$70K	949.21	-$9.16M	-$1.19	N/A
Emergent Biosolutions	$742.30M	0.41	$52.60M	-$3.55	N/A

eXoZymes has a beta of 2.93, indicating that its share price is 193% more volatile than the broader market. Comparatively, Emergent Biosolutions has a beta of 2.35, indicating that its share price is 135% more volatile than the broader market.

Emergent Biosolutions has a consensus price target of $10.00, suggesting a potential upside of 67.31%. Given Emergent Biosolutions' stronger consensus rating and higher possible upside, analysts clearly believe Emergent Biosolutions is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Emergent Biosolutions	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.17

Summary

Emergent Biosolutions beats eXoZymes on 10 of the 16 factors compared between the two stocks.

How does eXoZymes compare to Pyxis Oncology?

eXoZymes (NASDAQ:EXOZ) and Pyxis Oncology (NASDAQ:PYXS) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, institutional ownership and earnings.

eXoZymes has a beta of 2.93, suggesting that its stock price is 193% more volatile than the broader market. Comparatively, Pyxis Oncology has a beta of 1.31, suggesting that its stock price is 31% more volatile than the broader market.

39.1% of Pyxis Oncology shares are owned by institutional investors. 72.4% of eXoZymes shares are owned by insiders. Comparatively, 5.7% of Pyxis Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

eXoZymes has higher earnings, but lower revenue than Pyxis Oncology. eXoZymes is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
eXoZymes	$70K	949.21	-$9.16M	-$1.19	N/A
Pyxis Oncology	$11.04M	23.62	-$79.62M	-$1.41	N/A

In the previous week, eXoZymes had 1 more articles in the media than Pyxis Oncology. MarketBeat recorded 2 mentions for eXoZymes and 1 mentions for Pyxis Oncology. Pyxis Oncology's average media sentiment score of 1.89 beat eXoZymes' score of 0.93 indicating that Pyxis Oncology is being referred to more favorably in the news media.

Company	Overall Sentiment
eXoZymes	Positive
Pyxis Oncology	Very Positive

Pyxis Oncology has a consensus target price of $7.50, indicating a potential upside of 139.92%. Given Pyxis Oncology's stronger consensus rating and higher possible upside, analysts clearly believe Pyxis Oncology is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Pyxis Oncology's return on equity of -215.23% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
eXoZymes	N/A	-292.15%	-158.66%
Pyxis Oncology	N/A	-215.23%	-112.19%

Summary

Pyxis Oncology beats eXoZymes on 9 of the 15 factors compared between the two stocks.

How does eXoZymes compare to Akebia Therapeutics?

eXoZymes (NASDAQ:EXOZ) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings.

Akebia Therapeutics has a consensus price target of $3.75, suggesting a potential upside of 332.03%. Given Akebia Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Akebia Therapeutics is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Akebia Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Akebia Therapeutics had 2 more articles in the media than eXoZymes. MarketBeat recorded 4 mentions for Akebia Therapeutics and 2 mentions for eXoZymes. eXoZymes' average media sentiment score of 0.93 beat Akebia Therapeutics' score of 0.71 indicating that eXoZymes is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
eXoZymes	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Akebia Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

eXoZymes has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -13.54%. Akebia Therapeutics' return on equity of -88.88% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
eXoZymes	N/A	-292.15%	-158.66%
Akebia Therapeutics	-13.54%	-88.88%	-7.74%

33.9% of Akebia Therapeutics shares are held by institutional investors. 72.4% of eXoZymes shares are held by insiders. Comparatively, 4.3% of Akebia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Akebia Therapeutics has higher revenue and earnings than eXoZymes. Akebia Therapeutics is trading at a lower price-to-earnings ratio than eXoZymes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
eXoZymes	$70K	949.21	-$9.16M	-$1.19	N/A
Akebia Therapeutics	$236.20M	1.02	-$5.34M	-$0.11	N/A

eXoZymes has a beta of 2.93, suggesting that its share price is 193% more volatile than the broader market. Comparatively, Akebia Therapeutics has a beta of 0.26, suggesting that its share price is 74% less volatile than the broader market.

Summary

Akebia Therapeutics beats eXoZymes on 10 of the 16 factors compared between the two stocks.

Get eXoZymes News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EXOZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EXOZ vs. The Competition

Export

Metric	eXoZymes	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$67.29M	$3.94B	$7.18B	$12.88B
Dividend Yield	N/A	3.61%	2.54%	11.27%
P/E Ratio	-6.02	11.68	273.17	25.44
Price / Sales	949.21	1,401.93	637.42	103.51
Price / Cash	N/A	44.06	28.74	36.03
Price / Book	17.90	16.92	11.08	6.36
Net Income	-$9.16M	-$22.74M	$3.48B	$349.79M
7 Day Performance	3.02%	-0.13%	0.21%	-0.48%
1 Month Performance	53.98%	11.45%	7.75%	4.17%
1 Year Performance	-26.19%	55.66%	24.68%	15.11%

eXoZymes Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EXOZ eXoZymes	0.7649 of 5 stars	$7.16 -0.1%	N/A	-26.1%	$66.45M	$70K	N/A	29	Gap Down
ALEC Alector	2.7383 of 5 stars	$2.36 +4.4%	$3.63 +53.6%	-0.4%	$263.51M	$21.05M	N/A	270	Positive News
MGNX MacroGenics	2.9146 of 5 stars	$4.10 +0.7%	$6.33 +54.5%	+133.3%	$261.17M	$149.50M	N/A	430
EBS Emergent Biosolutions	3.411 of 5 stars	$5.07 +5.2%	$10.00 +97.2%	-28.5%	$260.47M	$742.90M	N/A	2,420
PYXS Pyxis Oncology	3.2817 of 5 stars	$3.08 -1.3%	$7.50 +143.5%	+152.3%	$256.90M	$13.86M	N/A	60

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EXOZ) was last updated on 8/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

eXoZymes (EXOZ) Competitors

EXOZ vs. ALEC, MGNX, EBS, PYXS, and AKBA

How does eXoZymes compare to Alector?

Summary

How does eXoZymes compare to MacroGenics?

Summary

How does eXoZymes compare to Emergent Biosolutions?

Summary

How does eXoZymes compare to Pyxis Oncology?

Summary

How does eXoZymes compare to Akebia Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EXOZ vs. The Competition

eXoZymes Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

eXoZymes (EXOZ) Competitors

EXOZ vs. ALEC, MGNX, EBS, PYXS, and AKBA

How does eXoZymes compare to Alector?

Do insiders and institutionals believe in ALEC or EXOZ?

Do analysts rate ALEC or EXOZ?

Which has more volatility & risk, ALEC or EXOZ?

Which has better earnings & valuation, ALEC or EXOZ?

Does the media prefer ALEC or EXOZ?

Is ALEC or EXOZ more profitable?

Summary

How does eXoZymes compare to MacroGenics?

Which has preferable earnings & valuation, MGNX or EXOZ?

Does the media prefer MGNX or EXOZ?

Is MGNX or EXOZ more profitable?

Do analysts rate MGNX or EXOZ?

Do insiders & institutionals hold more shares of MGNX or EXOZ?

Which has more volatility and risk, MGNX or EXOZ?

Summary

How does eXoZymes compare to Emergent Biosolutions?

Does the media refer more to EXOZ or EBS?

Is EXOZ or EBS more profitable?

Do insiders & institutionals have more ownership in EXOZ or EBS?

Which has preferable valuation & earnings, EXOZ or EBS?

Which has more risk and volatility, EXOZ or EBS?

Do analysts recommend EXOZ or EBS?

Summary

How does eXoZymes compare to Pyxis Oncology?

Which has more volatility and risk, EXOZ or PYXS?

Do institutionals & insiders have more ownership in EXOZ or PYXS?

Which has better valuation & earnings, EXOZ or PYXS?

Does the media refer more to EXOZ or PYXS?

Do analysts prefer EXOZ or PYXS?

Is EXOZ or PYXS more profitable?

Summary

How does eXoZymes compare to Akebia Therapeutics?

Do analysts rate EXOZ or AKBA?

Does the media refer more to EXOZ or AKBA?

Is EXOZ or AKBA more profitable?

Do insiders and institutionals believe in EXOZ or AKBA?

Which has preferable valuation & earnings, EXOZ or AKBA?

Which has more volatility & risk, EXOZ or AKBA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EXOZ vs. The Competition

eXoZymes Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools